Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.

Inclusion Criteria: Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment. Adequate hematologic status Adequate coagulation function Adequate hepatic function Adequate renal function Exclusion Criteria: Known primary tumors of central nervous system disease Known active brain metastases Known cardiopulmonary disease

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02216409.

This is a first-in-human, first-in-class, escalating dose trial of an antibody that

inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are

to define the safety profile of this new drug, and to determine a recommended dose and

schedule for potential additional trials.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationGilead

Description